Long-term effect of latanoprost/timolol fixed combination in patients with glaucoma or ocular hypertension: a prospective, observational, noninterventional study.
BACKGROUND
Prospective, observational studies that enroll large numbers of patients with few exclusion criteria may better reflect actual ongoing clinical experience than randomized clinical trials. Our purpose was to obtain efficacy and safety information from a cohort of subjects exposed to latanoprost/timolol fixed combination (FC) for ≥18 months using a prospective, observational design.


METHODS
In all, 577 office-based ophthalmologists in Germany switched 2339 patients with glaucoma or ocular hypertension to latanoprost/timolol FC for medical reasons. Follow-up visits were scheduled for every 6 months over 24 months; physicians followed usual care routines. Intraocular pressure (IOP), visual field status, optic nerve head findings, and adverse events were recorded. Efficacy parameters were evaluated for the per protocol (PP) population; the safety population included subjects receiving ≥1 drop of FC. Physicians rated efficacy, tolerability, and subject compliance at month 24.


RESULTS
Of the 2339 subjects switched to latanoprost/timolol FC (safety population), the primary reasons for switching were inadequate IOP reduction (78.2%) and desire to simplify treatment with once-daily dosing (29.4%; multiple reasons possible). In all, 1317 (56.3%) subjects completed the study, and 1028 (44.0%) were included in the PP population. Most discontinuations were due to loss to follow-up. Change in mean IOP from baseline to month 6 was -4.0 ± 4.31 mmHg, a reduction that was maintained throughout (P < 0.05 for change at all time points). By investigator assessments, optic disc parameters and visual field were stable over 24 months, and there was no relationship between IOP reduction over 24 months and development of a visual field defect. More than 90% of physicians rated latanoprost/timolol FC as "very good" or "good" for efficacy (PP population), tolerability, and compliance. The FC was safe and well tolerated. No change in iris color was reported by most subjects (83.1%) at month 24.


CONCLUSIONS
Over 24 months, latanoprost/timolol FC effectively lowers IOP levels and is well tolerated in patients with glaucoma or ocular hypertension who change from their previous ocular hypotensive therapy for medical reasons. Investigator assessments found optic disc parameters and visual field to be stable throughout 24 months of follow-up.
Schwenn
Oliver
O
Bürgerhospital Frankfurt am Main, Augenklinik, Frankfurt am Main, Germany. o.schwenn@burgerhospital-ffm.de
Heckmann
Barbara
B
Guzy
Claudia
C
Miller
Paul J
PJ
D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000959:Antihypertensive Agents / Q000008:administration & dosage*; D002648:Child; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination; D005260:Female; D005500:Follow-Up Studies; D005901:Glaucoma / Q000188:drug therapy* / Q000503:physiopathology; D006801:Humans; D007429:Intraocular Pressure / Q000187:drug effects*; D000077338:Latanoprost; D008297:Male; D008875:Middle Aged; D009798:Ocular Hypertension / Q000188:drug therapy* / Q000503:physiopathology; D011446:Prospective Studies; D011461:Prostaglandins F, Synthetic / Q000008:administration & dosage*; D013997:Time Factors; D013999:Timolol / Q000008:administration & dosage*; D016896:Treatment Outcome; D014794:Visual Fields / Q000187:drug effects; D055815:Young Adult
D000959:Antihypertensive Agents; D011461:Prostaglandins F, Synthetic; D000077338:Latanoprost; D013999:Timolol
Br J Ophthalmol. 1995 Jan;79(1):12-6
7880782
Am J Ophthalmol. 2007 Oct;144(4):533-40
17686450
Adv Ther. 2007 Mar-Apr;24(2):376-86
17565929
Graefes Arch Clin Exp Ophthalmol. 2002 Nov;240(11):893-9
12486510
J Glaucoma. 2003 Oct;12(5):393-8
14520147
Am J Ophthalmol. 1998 Oct;126(4):498-505
9780094
Arch Ophthalmol. 1978 Nov;96(11):2045-8
363105
Ophthalmology. 2004 Feb;111(2):276-82
15019375
Arch Ophthalmol. 2002 Oct;120(10):1268-79
12365904
J Ocul Pharmacol Ther. 2009 Apr;25(2):145-52
19284321
Am J Ophthalmol. 2000 Oct;130(4):429-40
11024415
Arch Ophthalmol. 2006 Apr;124(4):471-6
16606871
Invest Ophthalmol Vis Sci. 1977 Jul;16(7):623-4
873723
J Glaucoma. 1999 Feb;8(1):24-30
10084271
Arch Ophthalmol. 2010 Feb;128(2):165-72
20142538
Ophthalmic Surg. 1995 May-Jun;26(3):233-6
7651690
Arch Ophthalmol. 2003 Jan;121(1):48-56
12523884
Br J Ophthalmol. 1994 Dec;78(12):899-902
7819171
Br J Ophthalmol. 2004 Oct;88(10):1295-8
15377554
Arch Ophthalmol. 2002 Jul;120(7):915-22
12096962
Am J Ophthalmol. 1987 Feb 15;103(2):188-93
3812621
Br J Ophthalmol. 2009 Dec;93(12):1572-5
19628493
Arch Ophthalmol. 2002 Jun;120(6):701-13; discussion 829-30
12049574
Surv Ophthalmol. 2008 Nov;53 Suppl1:S107-20
19038618
Br J Ophthalmol. 2004 Feb;88(2):199-203
14736774
Ophthalmology. 2006 Jan;113(1):70-6
16263174
Am J Public Health. 1993 May;83(5):711-6
8484454
Ophthalmology. 1991 Jul;98(7):1079-82
1891217